within Pharmacolibrary.Drugs.ATC.A;

model A16AB12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0013,
    k12             = 3.2,
    k21             = 3.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AB12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Elosulfase alfa is a recombinant form of human N-acetylgalactosamine 6-sulfatase (GALNS), indicated for the treatment of mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A syndrome). It is an enzyme replacement therapy approved for use in patients with this rare, inherited, lysosomal storage disorder.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric and adult patients with MPS IVA following intravenous infusion of elosulfase alfa at 2 mg/kg once weekly over approximately 4 hours.</p><h4>References</h4><ol><li><p>Hendriksz, CJ (2016). Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome). <i>Expert review of clinical pharmacology</i> 9(12) 1521–1532. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2017.1260000&quot;>10.1080/17512433.2017.1260000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27855521/&quot;>https://pubmed.ncbi.nlm.nih.gov/27855521</a></p></li><li><p>Tomatsu, S, et al., &amp; Sly, WS (2015). Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?. <i>Molecular genetics and metabolism</i> 114(2) 195–202. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2014.05.013&quot;>10.1016/j.ymgme.2014.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24953405/&quot;>https://pubmed.ncbi.nlm.nih.gov/24953405</a></p></li><li><p>Tomatsu, S, et al., &amp; Orii, T (2007). Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. <i>Molecular genetics and metabolism</i> 91(1) 69–78. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2007.01.004&quot;>10.1016/j.ymgme.2007.01.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17336563/&quot;>https://pubmed.ncbi.nlm.nih.gov/17336563</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AB12;
